Skip to main content

Table 2 Baseline characteristics of the study population

From: Diabetes and risk of peripheral artery disease in patients undergoing first-time coronary angiography between 2000 and 2012 – a nationwide study

  Non-diabetes Diabetes
No CAD Single vessel disease Double vessel disease Triple vessel disease Diffuse disease No CAD Single vessel disease Double vessel disease Triple vessel disease Diffuse disease
N (%) 56.922 (61.52) 13.627 (14.73) 6.409 (6.93) 7.022 (7.59) 8.542 (9.23) 13.134 (54.80) 3.320 (13.85) 2.111 (8.81) 2.997 (12.50) 2.407 (10.04)
Sex, male (%) 33.361 (58.61) 9.499 (69.71) 4.777 (74.54) 5.594 (79.66) 4.860 (56.90) 8.376 (63.77) 2.298 (69.22) 1.574 (74.56) 2.299 (76.71) 1.528 (63.48)
Age, mean (IQR*) 63.17 (55–72) 63.51 (55–72) 66.95 (59–75) 69.57 (63–77) 66.13 (59–74) 63.84 (57–72) 63.93 (57–72) 65.91 (59–73) 67.29 (61–74) 64.96 (58–72)
Smoking (%) 14.042 (24.67) 4.983 (36.57) 2.064 (32.20) 1.923 (27.39) 2.100 (24.58) 3.089 (23.52) 1.030 (31.02) 624 (29.56) 787 (26.26) 559 (23.22)
B-blockers* (%) 22.256 (39.10) 3.112 (22.84) 1.931 (30.13) 2.516 (35.83) 2.723 (31.88) 6.609 (50.32) 1.040 (31.33) 795 (37.66) 1.244 (41.51) 916 (38.06)
Statins (%) 22.529 (39.58) 3.360 (24.66) 2.078 (32.42) 2.771 (39.46) 2.981 (34.90) 8.515 (64.83) 1.462 (44.04) 1.011 (47.89) 1.611 (53.75) 1.332 (55.34)
ACE-I* (%) 18.914 (33.23) 3.076 (22.57) 1.817 (28.35) 2.277 (32.43) 2.632 (30.81) 8.008 (60.97) 1.470 (44.28) 985 (46.66) 1.600 (53.39) 1.307 (54.30)
Spironolacton (%) 2.314 (4.07) 250 (1.83) 179 (2.79) 225 (3.20) 296 (3.47) 1.048 (7.98) 125 (3.77) 103 (4.88) 188 (6.27) 158 (6.56)
Loop diuretics (%) 7.595 (13.34) 885 (6.49) 605 (9.44) 903 (12.86) 1.055 (12.35) 3.430 (26.12) 508 (15.30) 385 (18.24) 693 (23.12) 554 (23.02)
ASA* (%) 25.578 (44.94) 3.630 (26.64) 2.234 (34.86) 3.026 (43.09) 3.132 (36.67) 7.880 (60.00) 1.283 (38.64) 991 (46.94) 1.589 (53.02) 1.124 (46.70)
VKA* (%) 4.711 (8.28) 563 (4.13) 332 (5.18) 360 (5.13) 717 (8.39) 1.393 (10.61) 187 (5.63) 131 (6.21) 179 (5.97) 252 (10.47)
Platlet inhibitors (%) 26.598 (46.73) 3.849 (28.25) 2.371 (36.99) 3.208 (45.68) 3.346 (39.17) 8.187 (62.33) 1.374 (41.39) 1.042 (49.36) 1.690 (56.39) 1.207 (50.15)
Digoxin (%) 2.248 (3.95) 311 (2.28) 199 (3.11) 266 (3.79) 468 (5.48) 924 (7.04) 137 (4.13) 114 (5.40) 181 (6.04) 199 (8.27)
Atrial Fibrillation (%) 5.007 (8.80) 791 (5.80) 425 (6.63) 518 (7.38) 1.041 (12.19) 1.543 (11.75) 258 (7.77) 189 (8.95) 244 (8.14) 3.621 (15.04)
IHD* (%) 4.812 (8.45) 1.134 (8.32) 859 (13.40) 1.234 (17.57) 780 (9.13) 1.789 (13.62) 401 (12.08) 398 (18.85) 702 (23.42) 281 (11.67)
Renal Disease (%) 897 (1.58) 132 (0.97) 91 (1.42) 123 (1.75) 144 (1.69) 383 (2.92) 74 (2.23) 60 (2.84) 82 (2.74) 81 (3.37)
Hypertension (%) 9.099 (15.99) 1.772 (13.00) 1.029 (16.06) 1.290 (18.37) 1.877 (21.97) 4.115 (31.33) 871 (26.23) 599 (28.38) 932 (31.10) 916 (38.06)
Thromboembolus(%) 4.128 (7.25) 893 (6.55) 511 (7.97) 763 (10.87) 829 (9.70) 1.308 (9.96) 326 (9.82) 228 (10.80) 409 (13.65) 273 (11.34)
  1. Continuous variables are presented as means (with standard deviation values) and discrete variables as percentages (%). B-blocker Beta-blocker, ACEI Angiotensin converting enzyme inhibitors, ASA Acetylsalicylic acid, VKA Vitamin K antagonist
  2. *Beta-Blockers *Angiotensin Converting Enzyme Inhibitors *Acetylsalicylic Acid *Vitamin K Antagonists *Ischemic Heart Disease *Interquartile range